Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | SMYD2 | Q9NRG4 | 3/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.33 |
| ▸ | TSHR | P16473 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | HRH1 | P35367 | 1/20 | 0.33 |
| ▸ | ABL1 | P00519 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8070836 | 0.87 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP3A4HTTSMYD2POLB | |
| SCHEMBL8071091 | 0.87 | SMN1; SMN2 (0.37) | SMN1; SMN2CYP3A4HTTSMYD2POLB | |
| SCHEMBL13311318 | 0.86 | SMYD2 (0.35) | SMN1; SMN2CYP3A4HTTSMYD2POLB | |
| SCHEMBL13311307 | 0.86 | SMYD2 (0.38) | SMN1; SMN2CYP3A4HTTSMYD2POLB | |
| SCHEMBL7781357 | 0.86 | POLB (0.39) | SMN1; SMN2CYP3A4HTTPOLBALDH1A1 | |
| SCHEMBL1291773 | 0.83 | LMNA (0.40) | SMN1; SMN2CYP3A4HTTSMYD2POLB | |
| SCHEMBL13311353 | 0.82 | SMYD2 (0.33) | SMN1; SMN2CYP3A4HTTSMYD2ALDH1A1 | |
| SCHEMBL22557449 | 0.82 | LMNA (0.39) | SMN1; SMN2CYP3A4HTTSMYD2ALDH1A1 | |
| SCHEMBL20475256 | 0.82 | SMYD2 (0.37) | SMN1; SMN2CYP3A4HTTSMYD2ALDH1A1 | |
| SCHEMBL13250794 | 0.82 | SMYD2 (0.37) | SMN1; SMN2CYP3A4HTTSMYD2ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2023-11-02 | — | — | US | disclosed |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | Azura Ophthalmics Ltd. (IL) | 2023-05-09 | — | — | US | disclosed |
| EP-3955937-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2022-02-23 | — | — | EP | disclosed |
| CN-114007625-A | Compounds and methods for treating ocular diseases | 阿祖拉眼科有限公司 | 2022-02-01 | — | — | CN | disclosed |
| US-20210230205-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2021-07-29 | — | — | US | disclosed |
| WO-2020212760-A2 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | Azura Ophthalmics Ltd. (IL) | 2020-10-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210230205-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | SMN1; SMN2 4780/4885CYP3A4 2463/4885HTT 4686/4885 |
| US-11643429-B2 | Compounds and methods for the treatment of ocular disorders | SERPINB1, KLKB1, MPO | SMN1; SMN2 4780/4885CYP3A4 2463/4885HTT 4686/4885 |
| US-20230348517-A1 | COMPOUNDS AND METHODS FOR THE TREATMENT OF OCULAR DISORDERS | SERPINB1, KLKB1, MPO | SMN1; SMN2 4780/4885CYP3A4 2463/4885HTT 4686/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.